1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. News
  7. Summary
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Delayed Nasdaq  -  05/25 04:00:00 pm EDT
4.630 USD   +0.22%
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating

11/11/2021 | 08:47am EDT


© MT Newswires 2021
All news about EXAGEN INC.
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
CI
05/13KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating
MT
05/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/11Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/11TRANSCRIPT : Exagen Inc., Q1 2022 Earnings Call, May 11, 2022
CI
05/11Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $10.4M, vs. Street Est of $10M
MT
05/11Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te..
GL
05/11Exagen Inc. Reports First Quarter 2022 Results
GL
More news
Analyst Recommendations on EXAGEN INC.
More recommendations
Financials (USD)
Sales 2022 53,4 M - -
Net income 2022 -35,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,23x
Yield 2022 -
Capitalization 75,3 M 75,3 M -
Capi. / Sales 2022 1,41x
Capi. / Sales 2023 1,14x
Nbr of Employees 221
Free-Float 58,9%
Chart EXAGEN INC.
Duration : Period :
Exagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXAGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 4,63 $
Average target price 16,40 $
Spread / Average Target 254%
EPS Revisions
Managers and Directors
Fortunato Ron Rocca President, Chief Executive Officer & Director
Kamal Adawi Chief Financial Officer & Secretary
Brian P. Birk Chairman
Debra Jeske Zack Chief Medical Officer
Anja Kammesheidt Chief Scientific Officer